Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial

BACKGROUND: Monoclonal antibodies targeting EGFR such as cetuximab or panitumumab represent a major step forward in the treatment of RAS wild type (WT) metastatic colorectal cancer (mCRC). Unfortunately, primary and acquired resistance mechanisms occur, with a huge percentage of patients succumbing...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Giulia, Ciardiello, Davide, Napolitano, Stefania, Martinelli, Erika, Troiani, Teresa, Latiano, Tiziana Pia, Avallone, Antonio, Normanno, Nicola, Di Maio, Massimo, Maiello, Evaristo, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969187/
https://www.ncbi.nlm.nih.gov/pubmed/36860319
http://dx.doi.org/10.3389/fonc.2023.1069370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969187/
https://www.ncbi.nlm.nih.gov/pubmed/36860319
http://dx.doi.org/10.3389/fonc.2023.1069370

Ejemplares similares